Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem Solh, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 2006.

https://doi.org/10.1182/blood-2019-123230

Published: 2019

Journal Articles

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2019) 134 (Supplement_1): 2014.

https://doi.org/10.1182/blood-2019-125229

Published: 2019

Journal Articles

Donor Cell Myeloma: A Unique Case

Guillermo J. Ruiz-Argüelles, FRCP, MACP, Alejandro Ruiz-Argüelles, MD, Javier Garces-Eisele, MD, Virginia Reyes-Nuñez, PhD, Maria Fernanda Vallejo-Villalobos, PhD, Gisela B. Gomez-Cruz, MD

Blood (2018) 132 (Supplement 1): 5743.

https://doi.org/10.1182/blood-2018-99-112526

Published: 2018

Journal Articles

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, CCRP, Katelin C Jackson, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem M Solh, MD, Scott R Solomon, MD

Blood (2017) 130 (Supplement 1): 4608.

https://doi.org/10.1182/blood.V130.Suppl_1.4608.4608

Published: 2017

Journal Articles

HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd

Blood (2015) 126 (23): 156.

https://doi.org/10.1182/blood.V126.23.156.156

Published: 2015

Journal Articles

Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced-Intensity Conditioning Regimen with Fludarabine and Busulfan from HLA-Matched Related Donor for Elderly Adult T-Cell Leukemia/Lymphoma: Results of Multicenter Phase II Study (ATL-NST-3)

Ryuji Tanosaki, MD PhD, Ilseung Choi, MD, Mototsugu Shimokawa, PhD, Atae Utsunomiya, MD PhD, Masahito Tokunaga, MD, Nobuaki Nakano, MD, Takahiro Fukuda, MD, Hirohisa Nakamae, Shigeki Takemoto, MD PhD, Shigeru Kusumoto, MD PhD, Takeaki Tomoyose, Eisaburo Sueoka, MD PhD, Motoaki Shiratsuchi, Youko Suehiro, MD, Takeharu Yamanaka, PhD, Jun Okamura, MD, Naokuni Uike

Blood (2014) 124 (21): 2580.

https://doi.org/10.1182/blood.V124.21.2580.2580

Published: 2014

Journal Articles

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Cameron D. Griffiths, MD, Ella S.M Ng, MSc., Bill Kangarloo, MSc., Tyler S Williamson, PhD, Reanne Booker, BSc, MSN, NP, Ping Yue, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Christopher Brown, MD, Andrew Daly, MD, FRCPC, James A Russell, MD, Jan Storek, MD, PhD

Blood (2013) 122 (21): 2116.

https://doi.org/10.1182/blood.V122.21.2116.2116

Published: 2013

Journal Articles

Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis

Alvaro Urbano-Ispizua, MD, Steven Z. Pavletic, MD, Mary E. D. Flowers, MD, Mei-Jie Zhang, PhD, Jeanette Carreras, MPH, Sonali M. Smith, MD, David G. Maloney, MD, PhD, Silvia Montoto, MD, Corey S. Cutler, MD, MPH, FRCPC, Stephen R Spellman, MBS, Mukta Arora, MD, MS, Wael Saber, MD, MS

Blood (2013) 122 (21): 2093.

https://doi.org/10.1182/blood.V122.21.2093.2093

Published: 2013

Journal Articles

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Amaani Hussain, Connie A. Sizemore, PharmD, Xu Zhang, PhD, Melissa Sanacore, PharmD, Stacey Brown, B.A., Karen Manion, RN, Lawrence E. Morris, Jr., MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2012) 120 (21): 3030.

https://doi.org/10.1182/blood.V120.21.3030.3030

Published: 2012

Journal Articles

Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis

Mehdi Hamadani, MD, Wael Saber, MD, MS, Jeanette Carreras, MPH, Kwang W. Ahn, PhD, Ginna G. Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Hillard M. Lazarus, MD

Blood (2012) 120 (21): 473.

https://doi.org/10.1182/blood.V120.21.473.473

Published: 2012

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database

Kenneth R. Carson, MD, Ryan Lynch, MD, Peter Riedell, MD, Ryan P. Roop, MD, Arun Ganti, MPHS, Weijan Liu, MS, Chadi Nabhan, MD, FACP, Tanya Wildes, MD, Kristen M. Sanfilippo, MD, Graham A Colditz, M.D., Dr.PH.

Blood (2012) 120 (21): 968.

https://doi.org/10.1182/blood.V120.21.968.968

Published: 2012

Journal Articles

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Mohamed L. Sorror, MD, MSc, Brent R. Logan, PhD, Xiaochun Zhu, MS, J. Douglas Rizzo, MD, Kenneth R. Cooke, MD, Philip L. McCarthy, Jr., MD, Vincent T Ho, MD, Barry Storer, PhD, Marcelo C Pasquini, MD, MS

Blood (2012) 120 (21): 733.

https://doi.org/10.1182/blood.V120.21.733.733

Published: 2012

Journal Articles

Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis

Mehdi Hamadani, MD, Wael Saber, MD, MS, Jeanette Carreras, MPH, Kwang W Ahn, PhD, Ginna G Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Hillard M Lazarus, MD

Blood (2012) 120 (21): 815.

https://doi.org/10.1182/blood.V120.21.815.815

Published: 2012

Journal Articles

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Blood (2012) 119 (26): 6373–6378.

https://doi.org/10.1182/blood-2012-03-417808

Published: 2012

Journal Articles

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Issa F Khouri, MD, Rima M Saliba, PhD, Martin Korbling, MD, Amin M Alousi, MD, Uday R Popat, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Partow Kebriaei, MD, Muzaffar H. Qazilbash, MD, Richard Champlin, MD, Roland L Bassett, Jr.

Blood (2011) 118 (21): 894.

https://doi.org/10.1182/blood.V118.21.894.894

Published: 2011

Journal Articles

Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,

Yvonne Hsu, Rima M Saliba, PhD, Grace-Julia Okoroji, Susan o'Brien, Alessandra Ferrajoli, MD, Lynne V. Abruzzo, MD, PhD, Richard Champlin, MD, Michael J Keating, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 4123.

https://doi.org/10.1182/blood.V118.21.4123.4123

Published: 2011

Journal Articles

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Cesar O. Freytes, MD, David H. Vesole, MD, PhD, Xiaobo Zhong, MS, Jennifer Le-Rademacher, PhD, Angela Dispenzieri, MD, Sagar Lonial, MD, Gustavo Milone, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 824.

https://doi.org/10.1182/blood.V118.21.824.824

Published: 2011

Journal Articles

Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)

Issa F. Khouri, Roland Bassett, Pedro Cano, Susan O'Brien, Yvonne Hsu, Carlos E. Bueso-Ramos, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Alessandra Ferrajoli, Richard Champlin, John McMannis, Marcelo Fernandez-Vina

Blood (2010) 116 (21): 2548.

https://doi.org/10.1182/blood.V116.21.2548.2548

Published: 2010

Journal Articles

Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

Grace-Julia Okoroji, Leandro de Padua Silva, Rima M Saliba, Martin Korbling, McLaughlin Peter, Chitra Hosing, Paolo Anderlini, Amin Alousi, Marcos de Lima, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Luis Fayad, Felipe Samaniego, MD, MPH, Nathan Fowler, Richard Champlin, Fredrick Hagemeister, Issa F Khouri

Blood (2010) 116 (21): 3510.

https://doi.org/10.1182/blood.V116.21.3510.3510

Published: 2010

NARROW

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Donor Cell Myeloma: A Unique Case

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd

Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced-Intensity Conditioning Regimen with Fludarabine and Busulfan from HLA-Matched Related Donor for Elderly Adult T-Cell Leukemia/Lymphoma: Results of Multicenter Phase II Study (ATL-NST-3)

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)

Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only